Trial Profile
An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Siltuximab (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections
- Focus Expanded access; Therapeutic Use
- Acronyms SISCO
- 17 Dec 2020 Results published in the EUSA Pharma Media Release.
- 28 May 2020 Status changed from recruiting to completed.
- 01 Apr 2020 According to an Ergomed media release, a manuscript is in preparation for submission to a leading medical journal.